Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.

Farzana A. Sayani, MD, Nizar J. Bahlis, MD, Peter Faris, PhD, Mary Lynn Savoie, MD, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Christopher B. Brown, MD, James A. Russell, MBBChir, FRCPE, Douglas A. Stewart, MD

Blood (2005) 106 (11): 2932.

https://doi.org/10.1182/blood.V106.11.2932.2932

Published: 2005

Journal Articles

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Mary Lynn Savoie, MD, Alexander Balogh, MD, M. Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD, PhD, Christopher B. Brown, MD, PhD, Diana M. Quinlan, A. Robert Turner, MD, Loree M. Larratt, MD, James A. Russell, MBBChir, FRCPE

Blood (2005) 106 (11): 2733.

https://doi.org/10.1182/blood.V106.11.2733.2733

Published: 2005

Journal Articles

Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.

Michelle Geddes, MD, Shabal B. Kangarloo, MSc, Farrukh Naveed, BSc, Ahsan M. Chaudhry, MD, Oluyemi Jeje, MD, Mary L. Savoie, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD, Christopher Brown, MD, Jan Storek, MD, PhD, Diana Quinlan, RN, Borje Andersson, MD, James A. Russell, MBBChir

Blood (2005) 106 (11): 1763.

https://doi.org/10.1182/blood.V106.11.1763.1763

Published: 2005

Journal Articles

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Douglas A. Stewart, MD, FRCPC, Peter Forsyth, MD, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, James R. Russell, MB, FRCPC

Blood (2004) 104 (11): 911.

https://doi.org/10.1182/blood.V104.11.911.911

Published: 2004

Journal Articles

A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) RE—Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL).

Douglas A. Stewart, MD, FRCPC, Michael Voralia, MD, FRCPC, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, Wanda Hasagawa, MD, FRCPC, Nizar Bahlis, MD, James R. Russell, MB, BChir, FRCPC

Blood (2004) 104 (11): 915.

https://doi.org/10.1182/blood.V104.11.915.915

Published: 2004

NARROW

Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Email alerts

ASH Publications

American Society of Hematology

Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only